Fig. (1). Relative risk reduction of the primary endpoint in different statin trials and remaining cardiovascular risk. Green: primary prevention trials, red: secondary prevention trials, orange: comparison between aggressive and moderate lipid-lowering. |
"Statins, for instance, lower the risk of heart attacks, and are prescribed to millions of adults all over the world. But there are several different sorts of statin. Because there is little commercial advantage to be gained by comparing the efficacy of the different varieties, no studies have done so in a useful way."http://www.economist.com/node/21563689
Current Pharmaceutical Design, 2011, 17, 861-870
Aucun commentaire:
Enregistrer un commentaire